UroGen Pharma Stock Quote URGN - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

11.01

Bid

10.30

Ask

11.47

Volume

315,828

10.8372 Day's Range 11.40

9.78 52 Week Range 20.70

Market Cap

464.616M

Previous Close

11.35

Open

11.26

Last Trade

11.01

Last Trade Time

Financial Volume

$ 3,517,071

VWAP

11.136

Average Volume (3m)

406,332

Shares Outstanding

42,199,414

Dividend Yield

PE Ratio

-4.54

Earnings Per Share (EPS)

-2.42

Revenue

82.71M

Net Profit

-102.24M

UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment opt... UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.urogen.com

Headquarters

Ra'anana, Center, Isr

Founded

UroGen Pharma Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker URGN. The last closing price for UroGen Pharma was $11.35. Over the last year, UroGen Pharma shares have traded in a share price range of $ 9.78 to $ 20.70.

UroGen Pharma currently has 42,199,414 shares outstanding. The market capitalization of UroGen Pharma is $478.96 million. UroGen Pharma has a price to earnings ratio (PE ratio) of -4.54.

UroGen Pharma to Present at Upcoming Investor Conferences

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will...

New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)

-No RFS difference based on use of JELMYTO for primary chemoablation versus post-endoscopic ablation as adjuvant therapy -No RFS difference based on tumor size, location, number of tumors or...

ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025

ENVISION Reports 79.6% Complete Response Rate at 3 Months, 82.3% Duration of Response at 12 Months, and Consistent Safety Profile UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated...

Form 8-K - Current report

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of...

Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

Favorable long-term durability data further supports JELMYTO as a primary treatment for low-grade upper tract urothelial cancer UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to...

UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC

UGN-102 demonstrated 82.3% duration of response (DOR) at 12 months in patients who achieved complete response at 3 months 79.6% complete response rate at 3 months in patients treated with...

UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that new data on...

New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

The Study Results are Published in the Journal of Urology Online UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat...

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.83	8.15324165029	10.18	11.645	10	214972	10.8497481	CS
4	0.18	1.6620498615	10.83	11.76	9.78	367352	10.58903565	CS
12	-1.04	-8.63070539419	12.05	13.1332	9.78	406332	11.27704005	CS
26	-4.98	-31.1444652908	15.99	17	9.78	503197	12.55725589	CS
52	-4.83	-30.4924242424	15.84	20.7	9.78	498513	14.32663566	CS
156	3.8	52.7045769764	7.21	24.13	4.85	309867	13.96371688	CS
260	-18.74	-62.9915966387	29.75	30.89	4.85	251025	15.51070382	CS

URGN - Frequently Asked Questions (FAQ)

What is the current UroGen Pharma share price?

The current share price of UroGen Pharma is $ 11.01

How many UroGen Pharma shares are in issue?

UroGen Pharma has 42,199,414 shares in issue

What is the market cap of UroGen Pharma?

The market capitalisation of UroGen Pharma is USD 478.96M

What is the 1 year trading range for UroGen Pharma share price?

UroGen Pharma has traded in the range of $ 9.78 to $ 20.70 during the past year

What is the PE ratio of UroGen Pharma?

The price to earnings ratio of UroGen Pharma is -4.54

What is the cash to sales ratio of UroGen Pharma?

The cash to sales ratio of UroGen Pharma is 5.61

What is the reporting currency for UroGen Pharma?

UroGen Pharma reports financial results in USD

What is the latest annual turnover for UroGen Pharma?

The latest annual turnover of UroGen Pharma is USD 82.71M

What is the latest annual profit for UroGen Pharma?

The latest annual profit of UroGen Pharma is USD -102.24M

What is the registered address of UroGen Pharma?

The registered address for UroGen Pharma is 9 HATAASIYA ST, PO BOX 2397, RA'ANANA, CENTER, 4365007

What is the UroGen Pharma website address?

The website address for UroGen Pharma is www.urogen.com

Which industry sector does UroGen Pharma operate in?

UroGen Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
TCTMTCTM Kids IT Education Inc	$ 0.764 (321.87%)	729.72M
REBNReborn Coffee Inc	$ 3.31 (63.05%)	55.54M
FCUVFocus Universal Inc	$ 5.87 (56.62%)	1.73M
SOPASociety Pass Inc	$ 1.54 (56.50%)	13.82M
CYCNCyclerion Therapeutics Inc	$ 3.92 (54.33%)	82.39M
ENVBEnveric Biosciences Inc	$ 2.0899 (-46.41%)	1.57M
NIVFNewGenIvf Group Ltd	$ 0.1489 (-42.51%)	14.8M
GLSTGlobal Star Acquisition Inc	$ 8.83 (-39.10%)	23.89k
PRPHProPhase Labs Inc	$ 0.2633 (-38.02%)	872.46k
SPGCSacks Parente Golf Inc	$ 0.5601 (-37.86%)	7.27M
TCTMTCTM Kids IT Education Inc	$ 0.764 (321.87%)	729.72M
NVDANVIDIA Corporation	$ 120.07 (-3.67%)	388.54M
RIMEAlgorhythm Holdings Inc	$ 0.02565 (5.12%)	338.75M
BHATBlue Hat Interactive Entertainment Technology	$ 0.0355 (-11.25%)	236.29M
CLEUChina Liberal Education Holdings Ltd	$ 0.1938 (30.77%)	234.8M